Bioabsorbable medical device with coating

Abstract

A biodegradable, bioabsorbable medical device with a coating for capturing progenitor endothelial cells in vivo and delivering a therapeutic agent at the site of implantation. The coating on the medical device is provided with a biabsorbable polymer composition such as a bioabsorbable polymer, copolymer, or terpolymer, and a copolymer or terpolymer additive for controlling the rate of delivery of the therapeutic agent.

What is claimed is: 
     
         1 . An expandable stent, comprising bioabsorbable material and a coating, wherein the expandable stent comprises a plurality of first meandering strut patterns forming an interconnected mesh, and at least one second strut pattern comprising a hoop circumferential about the longitudinal axis of the expandable stent, wherein the second strut pattern crystallizes when the stent is expanded, and wherein the coating comprises a ligand. 
     
     
         2 . The expandable stent of  claim 1 , wherein the second strut pattern further comprises a through-void. 
     
     
         3 . The expandable stent of  claim 1 , wherein the bioabsorbable material comprises at least poly-L-lactide (PLLA). 
     
     
         4 . The expandable stent of  claim 1 , wherein the ligand is configured to bind target cells in vivo. 
     
     
         5 . The expandable stent of  claim 4 , wherein the ligand is a small molecule, a peptide, an antibody, antibody fragments, or combinations thereof and the target cell is a progenitor endothelial cell antigen. 
     
     
         6 . The expandable stent of  claim 1 , wherein the bioabsorbable matrix comprises a natural or synthetic biodegradable polymer. 
     
     
         7 . The expandable stent of  claim 1 , wherein the bioabsorbable matrix comprises at least one of the group consisting of: dextran, tropoelastin, elastin, laminin, fibronectin, fibrin, collagen, basement membrane proteins, and cross-linked tropoelastin. 
     
     
         8 . The expandable stent of  claim 1 , comprising a pharmacological substance. 
     
     
         9 . The expandable stent of  claim 8 , wherein the pharmacological substance is at least one of the group consisting of: cyclosporin A, mycophenolic acid, mycophenolate mofetil acid, rapamycin, rapamycin derivatives, biolimus A9, CCI-779, RAD 001, AP23573, azathioprene, pimecrolimus, tacrolimus (FK506), tranilast, dexamethasone, corticosteroid, everolimus, retinoic acid, vitamin E, rosglitazone, simvastatins, fluvastatin, estrogen, 17β-estradiol, hydrocortisone, acetaminophen, ibuprofen, naproxen, fluticasone, clobetasol, adalimumab, sulindac, dihydroepiandrosterone, testosterone, puerarin, platelet factor 4, basic fibroblast growth factor, fibronectin, butyric acid, butyric acid derivatives, paclitaxel, paclitaxel derivatives, LBM-642, deforolimus, and probucol.